MX2022010794A - Sales y formas cristalinas de un agonista del receptor 1 asociado a aminas traza (taar1). - Google Patents
Sales y formas cristalinas de un agonista del receptor 1 asociado a aminas traza (taar1).Info
- Publication number
- MX2022010794A MX2022010794A MX2022010794A MX2022010794A MX2022010794A MX 2022010794 A MX2022010794 A MX 2022010794A MX 2022010794 A MX2022010794 A MX 2022010794A MX 2022010794 A MX2022010794 A MX 2022010794A MX 2022010794 A MX2022010794 A MX 2022010794A
- Authority
- MX
- Mexico
- Prior art keywords
- taar1
- agonist
- salts
- crystalline forms
- associated receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20164069 | 2020-03-19 | ||
| PCT/EP2021/056749 WO2021185878A1 (en) | 2020-03-19 | 2021-03-17 | Salts and crystalline forms of a taar1 agonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022010794A true MX2022010794A (es) | 2022-09-27 |
Family
ID=69846246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022010794A MX2022010794A (es) | 2020-03-19 | 2021-03-17 | Sales y formas cristalinas de un agonista del receptor 1 asociado a aminas traza (taar1). |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230120311A1 (https=) |
| EP (1) | EP4121428B1 (https=) |
| JP (2) | JP2023517729A (https=) |
| KR (1) | KR20220155575A (https=) |
| CN (1) | CN115279752A (https=) |
| AU (1) | AU2021238632A1 (https=) |
| BR (1) | BR112022016746A2 (https=) |
| CA (1) | CA3166331A1 (https=) |
| ES (1) | ES3044409T3 (https=) |
| IL (1) | IL294301A (https=) |
| MX (1) | MX2022010794A (https=) |
| TW (1) | TWI874616B (https=) |
| WO (1) | WO2021185878A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4731191A1 (en) * | 2022-08-12 | 2026-04-29 | F. Hoffmann-La Roche AG | Pharmaceutical compositions comprising 5-ethyl-4-methyl- n-[4-[(2 s) morpholin-2-yl]phenyl]-1h-pyrazole-3-carboxamide |
| WO2024222860A1 (zh) * | 2023-04-28 | 2024-10-31 | 江苏豪森药业集团有限公司 | 一种吗啉杂环类化合物的盐及其制备方法和应用 |
| CN117903050B (zh) * | 2024-03-15 | 2024-05-17 | 中国药科大学 | 阿立哌唑共晶及其药物组合物和应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| CN108713019B (zh) * | 2016-03-17 | 2021-06-15 | 豪夫迈·罗氏有限公司 | 具有作为taar的激动剂的活性的5-乙基-4-甲基-吡唑-3-甲酰胺衍生物 |
-
2021
- 2021-03-17 EP EP21712158.1A patent/EP4121428B1/en active Active
- 2021-03-17 IL IL294301A patent/IL294301A/en unknown
- 2021-03-17 BR BR112022016746A patent/BR112022016746A2/pt unknown
- 2021-03-17 ES ES21712158T patent/ES3044409T3/es active Active
- 2021-03-17 TW TW110109520A patent/TWI874616B/zh active
- 2021-03-17 CA CA3166331A patent/CA3166331A1/en active Pending
- 2021-03-17 KR KR1020227031814A patent/KR20220155575A/ko active Pending
- 2021-03-17 WO PCT/EP2021/056749 patent/WO2021185878A1/en not_active Ceased
- 2021-03-17 CN CN202180017438.9A patent/CN115279752A/zh active Pending
- 2021-03-17 AU AU2021238632A patent/AU2021238632A1/en active Pending
- 2021-03-17 MX MX2022010794A patent/MX2022010794A/es unknown
- 2021-03-17 JP JP2022555821A patent/JP2023517729A/ja active Pending
-
2022
- 2022-09-16 US US17/946,743 patent/US20230120311A1/en active Pending
-
2025
- 2025-08-07 JP JP2025132332A patent/JP2025166092A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TWI874616B (zh) | 2025-03-01 |
| IL294301A (en) | 2022-08-01 |
| WO2021185878A1 (en) | 2021-09-23 |
| EP4121428A1 (en) | 2023-01-25 |
| BR112022016746A2 (pt) | 2022-10-11 |
| JP2025166092A (ja) | 2025-11-05 |
| ES3044409T3 (en) | 2025-11-26 |
| EP4121428C0 (en) | 2025-08-13 |
| TW202140466A (zh) | 2021-11-01 |
| EP4121428B1 (en) | 2025-08-13 |
| JP2023517729A (ja) | 2023-04-26 |
| US20230120311A1 (en) | 2023-04-20 |
| KR20220155575A (ko) | 2022-11-23 |
| CA3166331A1 (en) | 2021-09-23 |
| CN115279752A (zh) | 2022-11-01 |
| AU2021238632A1 (en) | 2022-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022010794A (es) | Sales y formas cristalinas de un agonista del receptor 1 asociado a aminas traza (taar1). | |
| AR066420A1 (es) | Composicion farmaceutica suministrable oronasofaringeamente para la prevencion alivio / y o tratamiento de trastornos de miembros inquietos. uso. | |
| CL2024000552A1 (es) | Inhibidores de nlrp3 | |
| CO2021014292A2 (es) | Moduladores de la vía de respuesta integrada al estrés | |
| CO2022015927A2 (es) | Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 y métodos de uso | |
| AR127050A1 (es) | Compuestos espirocíclicos | |
| PE20081650A1 (es) | Combinaciones que comprenden formoterol y salmeterol y sales de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo[2,2,2]octano | |
| CO2019010078A2 (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
| MX2022005732A (es) | Derivado de amida y metodo de preparacion para el mismo y uso del mismo en medicina. | |
| CO6270360A2 (es) | Antagonistas no basicos del receptor de la hormona concentradora de melanina 1 y procedimientos | |
| PE20121084A1 (es) | Forma de dosificacion farmaceutica para administracion oral de un inhibidor de la familia bcl-2 | |
| CO2024015820A2 (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| MX2021015853A (es) | Analogos de 3-(5-metil-1,3-tiazol-2-il)-n-{(1r)-1-[2-(trifluor-met il)pirimidin-5-il]etil}benzamida. | |
| MX2023001671A (es) | Procedimiento y compuesto para su uso en el tratamiento y/o prevención de la netosis. | |
| BR112018015389A2 (pt) | derivado de 5-etil-4-metil-pirazol-3-carboxamida tendo atividade como agonista de taar | |
| PE20221455A1 (es) | Composicion farmaceutica que comprende selexipag | |
| CO2024017138A2 (es) | Compuestos amido heteroaromáticos útiles en el tratamiento de enfermedades hepáticas | |
| PE20070521A1 (es) | 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a | |
| MX2022001820A (es) | Sal y forma cristalina de un compuesto que tiene actividad agonista para el receptor 5 de esfingosina-1-fosfato [acido (2s,3r,4e)-2-amino-3-hidroxioctadeca-4-enil-1-fosforico (s1p5). | |
| CL2025001713A1 (es) | Sal maleato de un antagonista del receptor de melanocortina subtipo 2 cristalino (mc2r). | |
| CL2022001323A1 (es) | Derivados de 1,2,4-oxadiazol como agonistas del receptor hepático x | |
| CL2021000627A1 (es) | Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular | |
| MX2021012392A (es) | Compuestos, composiciones y metodos. | |
| DOP2024000018A (es) | Antagonistas del receptor muscarínico 4 y métodos de uso | |
| UY39007A (es) | Dextrometadona como tratamiento modificador de enfermedad para trastornos y enfermedades neuropsiquiátricas |